Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors Anne-Marie MaddoxMichael J. KeatingMari K Haddox Preclinical Studies Pages: 119 - 129
2-deoxy-D-glucose inhibits the antitumor effects of α-difluoromethylornithine on the growth of colon cancer in vivo Rami SaydjariJames R. Upp Jr.James C. Thompson Preclinical Studies Pages: 131 - 138
Disposition of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in mice Salah M. El DareerKathleen F. TilleryDonald L. Hill Preclinical Studies Pages: 139 - 146
Cytotoxicity of synthetic racemic ptilocaulin: A novel cyclic guanidine Regina L. RubenBarry B. SniderBetsy A. Dusak Preclinical Studies Pages: 147 - 154
Heterogeneous survival and cell kinetics responses of human astrocytoma clones to α-difluoromethylornithine in vitro S. C. BarrancoP. J. FordC. M. Townsend Jr. Preclinical Studies Pages: 155 - 161
Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma Jorge C. NadalCees J. van GroeningenGodefridus J. Peters Preclinical Studies Pages: 163 - 172
Experimental antitumor activity of BMY-28090, a new antitumor antibiotic John E. SchurigWilliam T. BradnerWilliam C. Rose Preclinical Studies Pages: 173 - 178
The effects of the anti-tumor agent mezerein on the cytotoxic capacity and oxidative metabolism of human blood cells Kevin BartonGia RandalArthur L. Sagone Jr. Preclinical Studies Pages: 179 - 188
Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer Ephraim S. CasperTracy CurleyThomas B. Hakes OriginalPaper Pages: 189 - 193
Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity James L. AbbruzzeseSusan SchmidtIrwin H. Krakoff OriginalPaper Pages: 195 - 201
Phase I study of vincristine and escalating doses of etoposide Don V. Jackson Jr.Julia M. CruzHyman B. Muss OriginalPaper Pages: 203 - 207
Phase I study of 4′-deoxydoxorubicin (esorubicin) in children with malignant solid tumors Charles B. PrattEdwin C. DouglassLoraine Avery OriginalPaper Pages: 209 - 211
Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative Katsuhiro InoueMakoto OgawaKatsuji Shinagawa OriginalPaper Pages: 213 - 218
A phase II study of spirogermanium in patients with advanced malignant lymphoma Cristiana SessaWim ten Bokkel HuinikFranco Cavalli OriginalPaper Pages: 219 - 222
Phase II trial of spirogermanium in advanced non-small cell lung cancer Thomas E. LadRichard R. BloughPatricia Hange OriginalPaper Pages: 223 - 224
Phase II evaluation of gallium nitrate by continuous infusion in breast cancer Khaled JabbouryDebbie FryeGabriel Hortobagyi OriginalPaper Pages: 225 - 229
Elliptinium: Phase II study in advanced measurable breast cancer Joseph TreatAndrew GreenspanPatrick J. Byrne OriginalPaper Pages: 231 - 234
Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study William P. McGuireJohn A. BlessingJackson Beecham OriginalPaper Pages: 235 - 238
Phase II trial of PCNU in breast carcinoma Jonathan M. RubinsSamul G. Taylor IV OriginalPaper Pages: 239 - 241
Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer C. Kent OsborneJohn B. CraigJudith Turner OriginalPaper Pages: 243 - 245
Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial Bruce DanaSteve DahlbergBill Tranum OriginalPaper Pages: 247 - 250
Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: An Illinois Cancer Council study Daniel H. ShevrinThomas E. LadNicholas J. Vogelzang OriginalPaper Pages: 251 - 253
Phase II trial of continuous drug infusions in advanced ovarian carcinoma: Acivicin versus vinblastine Robert H. EarhartJanardan D. KhandekarThomas E. Davis OriginalPaper Pages: 255 - 260
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector Carla I. FalksonHendre C. FalksonGeoffrey Falkson OriginalPaper Pages: 261 - 267
Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study Melissa A. Runge-MorrisMerrill S. KiesKendrith Rowland OriginalPaper Pages: 269 - 273
Cardiovascular rhythm effects of gamma recombinant DNA interferon Gregory G. FriessThomas D. BrownRomel C. Wrenn OriginalPaper Pages: 275 - 280
Inefficacy of methylglyoxal bis(guanylhydrazone) (MGBG) in patients with recurrent head and neck squamous cell carcinoma Carlos L. ArteagaGary M. Clark Letter to the Editor Pages: 281 - 283
Migratory thrombophlebitis during sandostatin (SMS 201-995, Sandoz) therapy for malignant carcinoid syndrome Larry NathansonAlex SochetMary Ellen Williams Letter to the Editor Pages: 285 - 287
